Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients
Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threat...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-11-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137921001358 |
| _version_ | 1818569401078644736 |
|---|---|
| author | Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha |
| author_facet | Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha |
| author_sort | Diego V. Clé |
| collection | DOAJ |
| description | Chimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications. |
| first_indexed | 2024-12-14T06:47:38Z |
| format | Article |
| id | doaj.art-32bfb39222994220bef5615e14a74f60 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-12-14T06:47:38Z |
| publishDate | 2021-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-32bfb39222994220bef5615e14a74f602022-12-21T23:12:59ZengElsevierHematology, Transfusion and Cell Therapy2531-13792021-11-0143S3S12Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patientsDiego V. Clé0Alexandre V. Hirayama1Alvaro J. Alencar2Luciano J. Costa3João V.P. Feliciano4Ederson R. Mattos5Ana C. Cordeiro6Marco Aurélio Salvino7George M. Navarro Barros8Marcos de Lima9Phillip Scheinberg10Renato L. Guerino-Cunha11Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil; Corresponding author at: Department of Medical Imaging, Hematology and, Clinical Oncology. Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Av. Bandeirantes, 3900, Vila Monte Alegre, Ribeirão Preto, SP, Brazil.Fred Hutchinson Cancer Research Center, Seattle, WA, USASylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USAO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USAHospital de Base, Faculdade de Medicina de Rio Preto (HB FAMERP), São José do Rio Preto, SP, BrazilFundação Amaral Carvalho, Jaú, SP, BrazilA.C. Camargo Cancer Center, São Paulo, SP, BrazilHospital Universitário Prof. Edgard Santos, Salvador, BA, BrazilHospital do Câncer de Barretos, SP, BrazilOhio State University, Columbus, OH, USAHospital A Beneficência Portuguesa, São Paulo, BrazilFaculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, BrazilChimeric antigen receptor T-cells (CAR-T cells) are a new modality of oncological treatment which has demonstrated impressive response in refractory or relapsed diseases, such as acute lymphoblastic leukemia (ALL), lymphomas, and myeloma but is also associated with unique and potentially life-threatening toxicities. The most common adverse events (AEs) include cytokine release syndrome (CRS), neurological toxicities, such as the immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, infections, and hypogammaglobulinemia. These may be severe and require admission of the patient to an intensive care unit. However, these AEs are manageable when recognized early and treated by a duly trained team. The objective of this article is to report a consensus compiled by specialists in the fields of oncohematology, bone marrow transplantation, and cellular therapy describing recommendations on the Clinical Centers preparation, training of teams that will use CAR-T cells, and leading clinical questions as to their use and the management of potential complications.http://www.sciencedirect.com/science/article/pii/S2531137921001358Cellular therapyCAR-T cellsComplication managementCytokine release syndromeNeurotoxicityCenter structuring |
| spellingShingle | Diego V. Clé Alexandre V. Hirayama Alvaro J. Alencar Luciano J. Costa João V.P. Feliciano Ederson R. Mattos Ana C. Cordeiro Marco Aurélio Salvino George M. Navarro Barros Marcos de Lima Phillip Scheinberg Renato L. Guerino-Cunha Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients Hematology, Transfusion and Cell Therapy Cellular therapy CAR-T cells Complication management Cytokine release syndrome Neurotoxicity Center structuring |
| title | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients |
| title_full | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients |
| title_fullStr | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients |
| title_full_unstemmed | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients |
| title_short | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients |
| title_sort | associacao brasileira de hematologia hemoterapia e terapia celular consensus on genetically modified cells i structuring centers for the multidisciplinary clinical administration and management of car t cell therapy patients |
| topic | Cellular therapy CAR-T cells Complication management Cytokine release syndrome Neurotoxicity Center structuring |
| url | http://www.sciencedirect.com/science/article/pii/S2531137921001358 |
| work_keys_str_mv | AT diegovcle associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT alexandrevhirayama associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT alvarojalencar associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT lucianojcosta associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT joaovpfeliciano associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT edersonrmattos associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT anaccordeiro associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT marcoaureliosalvino associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT georgemnavarrobarros associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT marcosdelima associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT phillipscheinberg associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients AT renatolguerinocunha associacaobrasileiradehematologiahemoterapiaeterapiacelularconsensusongeneticallymodifiedcellsistructuringcentersforthemultidisciplinaryclinicaladministrationandmanagementofcartcelltherapypatients |